Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of “Buy” from Analysts

Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) have earned an average rating of “Buy” from the seventeen research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, twelve have issued a buy recommendation and four have given a strong buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $56.00.

Several equities analysts have weighed in on SRRK shares. HC Wainwright raised their target price on Scholar Rock from $58.00 to $65.00 and gave the company a “buy” rating in a report on Friday, May 8th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, June 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Friday, July 17th. Canaccord Genuity Group started coverage on shares of Scholar Rock in a report on Monday, April 20th. They issued a “buy” rating and a $62.00 price target for the company. Finally, Barclays lifted their target price on Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th.

Scholar Rock Trading Down 3.7%

Shares of NASDAQ SRRK opened at $47.67 on Friday. The stock has a market cap of $5.71 billion, a price-to-earnings ratio of -13.28 and a beta of 0.67. The business has a 50 day simple moving average of $50.02 and a 200 day simple moving average of $47.47. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $58.49. The company has a debt-to-equity ratio of 0.71, a quick ratio of 8.64 and a current ratio of 8.64.

Scholar Rock (NASDAQ:SRRK) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the company earned ($0.67) EPS. On average, research analysts predict that Scholar Rock will post -3.23 earnings per share for the current fiscal year.

Insider Transactions at Scholar Rock

In other Scholar Rock news, Director Joshua Reed sold 3,053 shares of the business’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the sale, the director owned 19,518 shares of the company’s stock, valued at $1,048,897.32. The trade was a 13.53% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gilman sold 2,544 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.87, for a total transaction of $137,045.28. Following the completion of the sale, the director directly owned 59,511 shares in the company, valued at approximately $3,205,857.57. The trade was a 4.10% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 17,149 shares of company stock worth $923,108. 10.30% of the stock is currently owned by company insiders.

Institutional Trading of Scholar Rock

Several large investors have recently added to or reduced their stakes in SRRK. AQR Capital Management LLC raised its stake in shares of Scholar Rock by 609.3% in the first quarter. AQR Capital Management LLC now owns 57,294 shares of the company’s stock valued at $1,842,000 after acquiring an additional 49,217 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Scholar Rock by 12.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,046 shares of the company’s stock valued at $1,709,000 after buying an additional 5,831 shares during the last quarter. Millennium Management LLC lifted its position in Scholar Rock by 37.4% during the 1st quarter. Millennium Management LLC now owns 200,255 shares of the company’s stock worth $6,438,000 after buying an additional 54,555 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Scholar Rock by 25.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 169,825 shares of the company’s stock worth $5,460,000 after purchasing an additional 34,594 shares in the last quarter. Finally, Strs Ohio acquired a new position in Scholar Rock during the 1st quarter worth $77,000. 91.08% of the stock is owned by institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).